A treatment for ataxia.

R. Currier
DOI: https://doi.org/10.1001/ARCHNEUR.1995.00540290035014
1995-05-01
Archives of Neurology
Abstract:How cana medication work on one side of the Rhine and not the other? The articles by Trouillas et al 1 and Wessel et al 2 in this issue of theArchivesillustrate in many ways the causes and types of disagreement about the effect of an experimental drug on a constellation of symptoms. The levorotatory form of hydroxytryptophan (l-5-hydroxytryptophan), a serotonin precursor, has been used for a decade or more by Trouillas et al 1 and others in an attempt to treat ataxia of various causes. Studies have evolved from early unblinded attempts to these two double-blinded studies. 1,2 Trouillas and coworkers originally found the most benefit in treating those patients with noninherited ataxia. In the present study, 1 they concentrated on 19 persons with Friedreich's ataxia from 11 centers, whereas the study by Wessel and coworkers 2 included 39 patients from three centers: 19 with Friedreich's
What problem does this paper attempt to address?